|MDACC Study No:||2010-0065 (clinicaltrials.gov NCT No: NCT01169636)|
|Title:||Phase I Study of Panobinostat Plus ICE Chemotherapy Followed by A Randomized Phase-II Study of ICE compared with Panobinostat Plus ICE For Patients With Relapsed and refractory Classical Hodgkin Lymphoma|
|Principal Investigator:||Yasuhiro Oki|
|Treatment Agent:||Carboplatin; Etoposide; Ifosfamide; LBH589 "B" (oral) ; Panobinostat|
|Study Description:||The goal of this clinical research study is to find the highest tolerable dose |
of the combination of the drugs ifosfamide, carboplatin, and etoposide (a
routine chemotherapy called ICE) and panobinostat and that can be given to
patients with relapsed or refractory Hodgkin's lymphoma.
The safety of this drug combination will also be studied.